SecBot SecBot
EFFECT ·Filed May 26, 2026

TARA

Protara Therapeutics, Inc.
BEARISH
Impact 5/10
Horizondays Processed5mo ago SEC9999999995-26-001748
IPO/offering going effective
Actionable Insight ▼ Bearish

Traders should watch for a prospectus supplement announcing a priced offering, which typically follows effectiveness within days to weeks for clinical-stage biotechs. Monitor insider buying/selling patterns for signals on whether management views the current valuation as attractive ahead of potential dilution.

DirectionBearish
Confidencemedium
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.80
T+0 close · May 26, 2026 · via day close
Latest settled
−17.50%
T+60 · $3.96
Vs SPY
−20.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 26 $4.80entry
  2. T+1 · 6mo ago −0.83%α −0.85% · $4.76
  3. T+5 · 6mo ago −9.58%α −10.80% · $4.34
  4. T+20 · 5mo ago −15.52%α −13.57% · $4.06
  5. T+60 · 3mo ago −17.50%α −20.22% · $3.96

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Protara Therapeutics' registration statement on Form S-3 (File No. 333-295862) was declared effective on May 22, 2026. This enables the company to conduct primary and/or secondary offerings of securities at any time, creating potential dilution overhang for common stock shareholders.

Key Facts

  • Form S-3 shelf registration became effective May 22, 2026.
  • Registration covers issuance of common stock, preferred stock, warrants, debt securities, and/or units.
  • No specific pricing, amount, or intended use of proceeds was disclosed in the effectiveness notice.
  • Company is a clinical-stage biotech with $277M market cap and 93% analyst buy rating.

Financial Impact

Undisclosed, no offering size or terms were provided in the effectiveness notice. Shelf registration is effective immediately, so the company can conduct offerings at any time.

dilutionmarket capitalizationshare price

Risk Factors

  • Immediate risk: company may announce a dilutive offering at any time now that the shelf is effective.
  • Clinical-stage biotech with no approved products, pipeline failure could compound dilution risk.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001748
Document: 9999999995-26-001748-index.html9999999995-26-001748
Document: 9999999995-26-001748.txt9999999995-26-001748

Track record

13 reports on TARA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.52 Now $2.38 +5.56% settles Feb 12
  2. Nov 6, 202610d ago 8-K Neutral 4/10 No price data
  3. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $2.30 Now $2.38 +3.48% settles Feb 4
  4. Oct 15, 20264w ago Press Release Neutral 3/10 Entry $2.40 Now $2.38 −0.83% settles Jan 12
  5. Aug 11, 202613w ago 8-K Neutral 4/10 No price data
  6. Aug 11, 202613w ago Press Release Neutral 4/10 Entry $3.91 to $2.35 Now $2.38 −39.13% ▼ −39.90% −39.41% vs SPY
  7. Jun 29, 202620w ago 8-K Neutral 2/10 Entry $3.82 to $3.54 Now $2.38 −37.70% ▼ −7.33% −10.15% vs SPY
  8. May 26, 202625w ago EFFECT Bearish 5/10 Viewing Entry $4.80 to $3.96 Now $2.38 +50.42% ▲ +17.50% +20.22% vs SPY
  9. May 15, 202626w ago Press Release Bullish 7/10 Entry $5.10 to $3.91 Now $2.38 −53.33% ▼ −23.33% −27.85% vs SPY
  10. May 13, 202626w ago 8-K Neutral 4/10 No price data
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 26, 2026